S&P Futures
4,464.33-9.92(-0.22%)Dow Futures
34,696.80-52.20(-0.15%)Nasdaq Futures
15,486.67-31.08(-0.20%)Russell 2000 Futures
2,241.04+7.84(+0.35%)Crude Oil
70.06-1.91(-2.65%)Gold
1,758.70+7.30(+0.42%)
Aridis Pharmaceuticals, Inc. (ARDS)
Chart Events
Performance Outlook
| Previous Close | 3.8900 |
| Open | 3.8500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1100 |
| Day's Range | 3.6600 - 4.0200 |
| 52 Week Range | 3.5400 - 8.5000 |
| Volume | 43,636 |
| Avg. Volume | 170,996 |
| Market Cap | 45.156M |
| Beta (5Y Monthly) | 0.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4360 |
| Earnings Date | Mar 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
- PR Newswire
Aridis Pharmaceuticals Announces Second Quarter 2021 Results
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2021.
- Zacks
Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for
ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 2,473,778 shares of the Company's common
